{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:53:42Z","timestamp":1792173222950,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:p>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.<\/jats:p>\n                  <jats:p>\n                    Patients with Kirsten rat sarcoma viral oncogene homolog ( KRAS)\u2013mutated non\u2013small-cell lung cancer (NSCLC) and untreated CNS metastases have a worse prognosis than similar patients without KRAS mutations. Adagrasib has previously demonstrated CNS penetration preclinically and cerebral spinal fluid penetration clinically. We evaluated adagrasib in patients with KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -mutated NSCLC and untreated CNS metastases from the KRYSTAL-1 trial (ClinicalTrials.gov identifier: NCT03785249 ; phase Ib cohort), in which adagrasib 600 mg was administered orally, twice daily. Study outcomes included the safety and clinical activity (intracranial [IC] and systemic) by blinded independent central review. Twenty-five patients with KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -mutated NSCLC and untreated CNS metastases were enrolled and evaluated (median follow-up, 13.7 months); 19 patients were radiographically evaluable for IC activity. Safety was consistent with previous reports of adagrasib, with grade 3 treatment-related adverse events (TRAEs) in 10 patients (40%) and one grade 4 (4%) and no grade 5 TRAEs. The most common CNS-specific TRAEs included dysgeusia (24%) and dizziness (20%). Adagrasib demonstrated an IC objective response rate of 42%, disease control rate of 90%, progression-free survival of 5.4 months, and median overall survival of 11.4 months. Adagrasib is the first KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    inhibitor to prospectively demonstrate IC activity in patients with KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -mutated NSCLC and untreated CNS metastases, supporting further investigation in this population.\n                  <\/jats:p>","DOI":"10.1200\/jco.23.00046","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T15:59:16Z","timestamp":1686931156000},"page":"4472-4477","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":84,"title":["Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With\n                    <i>\n                      KRAS\n                      <sup>G12C<\/sup>\n                    <\/i>\n                    -Mutated Non\u2013Small-Cell Lung Cancer Who Have Untreated CNS Metastases"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03785249","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6699","authenticated-orcid":false,"given":"Marcelo V.","family":"Negrao","sequence":"first","affiliation":[{"name":"Department of Thoracic\/Head & Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, Fairfax, VA"},{"name":"US Oncology Research, The Woodlands, TX"},{"name":"NEXT Oncology, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7397-2009","authenticated-orcid":false,"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Weiss","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-3811","authenticated-orcid":false,"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[{"name":"Henry Ford Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Velastegui","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-5712","authenticated-orcid":false,"given":"Hirak","family":"Der-Torossian","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-1543","authenticated-orcid":false,"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, New York University Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.03.002"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120858"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.12.013"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030638"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.030"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143572"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.005"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.05.026"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122132"},{"key":"b10","first-page":"171","volume":"3","author":"Parikh NR","year":"2015","journal-title":"J Radiosurg SBRT"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97566-z"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02052"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0383"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70057-4"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010017"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017736252"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00336"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.185"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1159\/000525341"},{"key":"b23","first-page":"100428","volume":"3","author":"Yeh J","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"b24","first-page":"100442","volume":"4","author":"Kunimasa K","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.547"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.00046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T18:01:42Z","timestamp":1695837702000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.00046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":25,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,10,1]]}},"alternative-id":["10.1200\/JCO.23.00046"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.00046","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]},"assertion":[{"value":"2023-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}